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Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe
secondary hyperparathyroidism. The purpose of the present study was
to examine the effect of a two day and a five day administration of
22-oxa-calcitriol (OCT) on calcium metabolism in rats with advanced
chronic renal failure and severe secondary hyperparathyroidism. A first
series of 27 uremic rats received either placebo, OCT or calcitriol (0.3
ug i.p./rat) 48 and 24 hours before sacrifice. A second series of 18
uremic rats received either placebo, OCT (0.3 g i.p./rat) or calcitriol
(0.05 sg i.p./rat) for five days. We found that after 48 hours (series 1)
both calcitriol and OCT increased blood ionized calcium (Ca21 as
compared to vehicle (1.23 0.04 and 1.10 0.02 mri, P < 0.01 and P
< 0.05, respectively vs. control, 1.02 0.03 mM). Duodenal Ca
transport (S/M) using the everted gut sac technique was not stimulated
by OCT. even though it increased from 2.8 0.4 to 7.0 0.6 (P < 0.01)
with calcitriol. In contrast, duodenal calbindin-D9k mRNA expression
and protein content increased to a similar extent with OCT and
calcitriol. Calcitriol was more potent in reducing plasma iPTH134 levels
than OCT: 344 75 pg/mI (calcitnol) versus 632 46 pg/mI (OCT)
compared with 897 74 pg/ml (control), P < 0.01. In the second series
of rats, the injection of OCT (0.3 g i.p./rat) over five days was less
effective than the lower dose of calcitnol (0.05 ig i.p./rat) in reducing
circulating iPTH: 110 26 (calcitriol) and 281 64 (OCT) versus 624
135 pg/mI (control), P < 0.01. The same tendency was observed for
both compounds regarding the increase in blood Ca2 1.36 0.04
(calcitriol) and 1.26 0.04 (OCT) versus 1.05 0.06 m (control), P <
0.01. S/M was significantly increased by calcitriol but not by OCT: 4.0
0.3 (calcitriol) versus 3.0 0.09 (OCT) versus 2.6 0.3 (control), P
<0.05. In conclusion, in this model of secondary hyperparathyroidism,
OCT as well as calcitriol treatment increased blood Ca2 and decreased
circulating iPTH levels. However, the effects of OCT on both param-
eters were less marked than those of calcitriol. Both vitamin D
derivatives were equivalent in increasing duodenal calbindin-D9K
mRNA and protein synthesis, but only calcitriol stimulated intestinal
calcium transport.
Secondary hyperparathyroidism is a common finding in pa-
tients with chronic renal failure [1]. It is established that the
reduction of renal 1 ,25(OH)2D3 (calcitriol) synthesis is one of
the principal mechanisms leading to the secondary hyperpara-
thyroidism in these patients. It has been shown that calcitriol
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possesses direct suppressive action on PTH synthesis [2—4].
Therefore, a recommended measure in the management of
these patients is the administration of the active vitamin D
compound, 1 ,25(OH)2D3.
However, the potent hypercalcemic action of calcitriol is an
undesired effect and a major limitation to its use, especially
when administered at high doses. Thus, theoretically a vitamin
D analog that is able to suppress PTH without effects on plasma
calcium and phosphate levels would be an ideal tool to control
secondary hyperparathyroidism. The 1 ,25(OH)2-22-oxa-D3
(OCT) derivative is one of these novel analogs. It is a potent
immunoregulator in mice without inducing hypercalcemia [5].
Moreover, OCT appears to be 50 to 100 times less effective than
calcitriol in releasing 45Ca from prelabeled fetal mouse calvana
[6]. In addition, OCT blocks calcitriol production and acceler-
ates calcitriol breakdown with a concomitant reduction of its
plasma levels [7, 81. Recently, it has been shown that the
short-term i.p. administration of a high dose of OCT to rats in
the early phase of chronic renal failure was capable of suppress-
ing PTH mRNA expression and decreasing plasma 1PTH levels
to the normal range without hypercalcemia [9]. Similar findings
have been reported in normal rats and uremic dogs [10, 11].
Thus, it has been suggested that OCT could be a better
candidate for the treatment of secondary hyperparathyroidism
than the parent compound, calcitriol.
Our present study in uremic rats with severe secondary
hyperparathyroidism was designed to compare the effects of a
high dose of OCT with that of a high dose of calcitriol on plasma
Ca, PTH and several other parameters of calcium and phos-
phate metabolism.
Methods
Preparation of animals
Male 12 to 14 week old Wistar AF rats (IFFA CREDO, Lyon,
France) weighing 250 to 300 g were fed ad libitum with a
phosphate-rich diet containing 1.2% P, 0.6% Ca, 16% casein,
and 2000 lU/kg vitamin D3 to obtain severe secondary hyper-
parathyroidism. Access to food and distilled water was not
restricted until sacrifice.
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Creation of chronic renal failure
Chronic renal failure was created by a standard two-step
operation [12]. Rats were anesthetized by pentobarbital given
i.p. During the first surgery, 2/3 of the left kidney were removed
by cutting off both poles after decapsulation, and complete
hemostasis was obtained by electrocoagulation. Seven days
later, total right nephrectomy was performed.
Three to four weeks after the creation of uremia, blood
samples were obtained by heart puncture under light ether
anesthesia and plasma urea and creatinine measured. Compa-
rable rat groups were formed according to the level of plasma
urea and creatinine. Two subsequent studies were performed
using different doses of OCT and calcitriol and different time
schedules of administration.
Two-day administration (series I)
Seven rats (control) received vehicle solution (340 sl pro-
pylene glycol), ten rats received calcitriol, 0.3 sg/rat (250
pmolJlOO g body wt) dissolved in propylene glycol, and ten rats
received OCT, 0.3 pg/rat (250 pmol/l00 g body wt) also dis-
solved in propylene glycol. Treatments were given intrapento-
neally (i.p.) 48 and 24 hours before sacrifice.
Five-day administration (series2)
Five rats (control) received vehicle solution (340 pi propylene
glycol), seven rats received calcitriol, 0.05 pg/rat (40 pmolJlOO
g body wt), and six rats received OCT, 0.3 pg/rat (250 pmol/l00
g body wt). Both compounds were dissolved in propylene
glycol. Treatments were given intraperitoneally (i.p.) each day
for five days prior to sacrifice,
Calcitriol was graciously supplied by Roche Laboratories,
France and OCT by Chugai Pharmaceutical Co., Tokyo, Japan.
Blood biochemistry
Animals were sacrificed by aortic puncture and blood sam-
ples immediately obtained after duodenum sampling. An aliquot
was used for blood ionized Ca and pH determination (ICA 1
Ionized Calcium Analyzer, Radiometer, Copenhagen, Den-
mark). The remaining blood was centrifuged at 1500 g for 20
minutes. Plasma was stored at —50°C until assays were per-
formed. Plasma total calcium, phosphorus, total protein con-
centration, plasma alkaline phosphatases, urea and creatinine
were determined by standard laboratory methods performed on
multiparametnc analyzer (Hitachi 717 analyzer, Boehringer,
Mannheim, Germany).
Immunoreactive plasma parathyroid hormone (iPTH) was
measured with the INS-PTH34 radioimmunoassay kit from
Nichols Institute Laboratories, California, USA [13]. To vali-
date our iPl'H measurements we performed an additional study
comparing the results obtained from the above kit with deter-
minations using a rat PTH (IRMA) kit (Immutopics, Inc.,
California, USA) [14]. We found an excellent correlation for
PTH values measured with the two kits (N = 19, r = 0.98, P <
0.001).
Calcium transport studies
At the time of sacrifice, studies of active calcium transport
across the intestinal wall were performed by everted gut sac
technique, as described by Martin and Deluca [15]. Briefly, rats
were anesthetized and the duodenum rapidly removed just
before aortic puncture. The proximal duodenum (5.5 cm) was
everted, filled with the incubation medium and immersed in the
same medium. This medium consisted of 0.25 mti CaCI2; 125
mM NaCl, 10 m fructose, 30 mrt Tris-HCI buffer (pH 7.4) and
45Ca (20,000 counts/mm per ml). The outside medium was
oxygenated continuously and maintained at 37°C. After 90
minutes the gut sac was removed and the 45Ca content of the
inner and the outer medium determined using LKB Wallac,
RackBeta, liquid scintillation counter. Results were expressed
as the ratio (S/M) of the 45Ca concentration of inside (serosal, S)
solution to the outside (mucosal, M) solution.
Duodenal calbindin-D9K
In series 1 rats, the distal 3 cm of duodenal mucosa were
scrapped off with a glass slide and divided in two aliquots to
measure duodenal cytosolic calbindin-D9k and calbindin-D9k
mRNA. Samples were quickly frozen in liquid nitrogen and
stored at —80°C. For calbindin-D9k determination, the mucosal
tissue was homogenized in 4 vol Tris buffer (14 m Tris-HC1,
120 m NaCI, 3 mM KCI, pH 7.4) using a Potter-Elvehjem
homogenizer. The homogenate was then centrifuged at 100,000
g for 60 minutes. The S100 supernatant was removed and stored
at —20°C. The protein content of homogenate and SlOO super-
natant was measured in duplicate by Lowry procedure [16].
Duodenal cytosolic calbindin-D9k of S100 supernatant was
quantitated in triplicate by radioimmunoassay using 1251-cal-
bindin-D9k and rabbit antiserum against purified rat calbindin-
D9k [17]. Duodenal calbindin-D9k concentrations have been
expressed as pg/mg of total soluble protein.
RNA preparation and Northern blot hybridization
Total RNA from the duodenal mucosa was extracted with
guanidium thiocyanate-phenol-chloroform as described by
Chomczynski and Sacchi [18]. RNA was denatured in 50%
formamide, 6% formaldehyde, 5% glycerol, 0.25% bromophe-
nol blue, 0.02 M 3 (N-morpholino) propane sulfonic acid
(MOPS), 5 m Na acetate, 1 mi EDTA. Ten micrograms of
denatured total RNA, to which ethidium bromide was added
(0.05 pg/.d), were electrophoresed on 1% horizontal agarose gel
containing 2% formaldehyde for 90 minutes at 80 V in 0.02 M
MOPS, 5 m Na acetate, and 1 mrt EDTA at pH 7.0.
After electrophoresis, the gel was soaked in bidistilled water
during 10 minutes and photographed under UV light: the
mRNAs 28S and 18S, visualized by ethidium bromide fluores-
cence, served as indicators of quality of total RNA. RNA was
then capillary transferred to nylon membrane (Hybond N+,
Amersham) using 0.05 M NaOH for two hours. The filter was
washed 10 minutes in twofold standard saline citrate (SSC: 0.15
M NaC1, 0.015 M Na citrate, pH 7.0), air dried and stored at 4°C
before prehybridization.
The calbindin-D9k cDNA probe was a gift from M. Thomas-
set [19]. It was radiolabeled with 32P-dCTP (Amersham,
France) by a random priming procedure according to the
manufacturer's instructions. The unincorporated nucleotides
were removed by chromatography on Sephadex G-50(Pharma-
cia, Sweden). The specific activity of the cDNA probe was
about I to 2 106 cpmlng. A f3-actin probe [201 was labeled the
same way and used as internal control. Filters were prehybrid-
ized at least four hours at 42°C in prehybridization buffer [50%
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Table 1. Biochemistries in chronic renal failure rats at four weeks (series 1) and three weeks (series 2) after 5/6 nephrectomy
Biochemistry
group
Series I Series 2
Control Calcitriol OCTControl Calcitriol OCT
Number of animals 7 10 10 5 7 6
P-phosphate m 5.42 0.5 6.2 0.7 6.0 0.41 4.3 0.77 4.54 0.6 4.74 0.8
P-creatinine pii 162 22 171 19 160 13 170 40 175 20 142 23
P-ureamM 21±3 23±3 21±2 20±6 23±4 16±3
P-alkaline phosphatases 98 6 86 10 93 5 117.5 20 76.9 5.4 114.1 16
lU/liter
P-total protein g/liter 52 1 54 2 51 1 52 1 50 1 50 2
Blood pH
Blood iCa mi
7.26 0.03
1.02 0.03
7.29 0.04
1.23 O.O4
7.27 0,03
1.1 0.02t
7.31 0.06
1.05 0.06
7.36 0.05
1.36 0.04°
7.28 0.04
1.26 004d
Abbreviations are: P, plasma; OCT, 22-oxa-calcitriol. Values are means SE.
P < 0.01, calcitriol vs. control and OCT
b P < 0.05, OCT vs. control
c.d P < 0.01, calcitriol and OCT vs. control
(vol/vol) deionized formamide, 4 m NaH2PO4, pH 7.0, five-
fold SSC, 0.2% BSA, 0.2% Ficoll 400, 0.2% polyvinylpyroli-
done] containing 100 sg/ml sonicated denatured salmon sperm
DNA. The hybridization was performed 16 hours at 42°C in the
above buffer to which the 32P-labeled probe (0.2 to 0.3 ng/ml)
was added. The filters were then washed (3 washes of 20 mm in
twofold SSC-0.1% SDS at room temperature followed by 2
washes of 1 hr in onefold SSC-0. 1% SDS at 60°C), and air dried
before autoradiography at —80°C using Amersham Hyperfilm.
The autoradiograms of the Northern blots were analyzed by
densitometry (Scan Jet II p, Hewlett Packard, France). The
abundance of calbindin-D9k mRNA was quantified by densito-
metric analysis (Scan Analysis, Biosoft, UK) of peak areas,
which has been previously shown to be directly proportional to
the amount of radioactivity (32P cDNA bound to calbindin-D9k
mRNA) [21]. The area for each peak was normalized to the
peak area obtained for the same lane with the f3-actin probe.
Results are expressed in arbitrary units as the ratio calbindin-
D9k/j3-actin.
Statistical analysis
Results have been expressed as means SEM, and the
statistical significance has been determined by unpaired Stu-
dent's t-test or ANOVA test with Statview program as appro-
priate. P values less than 0.05 were considered significant.
Results
Two-day administration (series 1)
Plasma biochemistry. Plasma biochemistry performed at
sacrifice showed no difference between the three groups in
terms of plasma phosphate, creatinine, urea, alkaline phos-
phatases and total protein (Table 1).
Plasma iPTH134 and blood Ca2. Figure 1 shows the effects
of OCT and calcitriol on circulating iVfH134 levels. Whereas
plasma iPTH134 concentration decreased from 897 74 (con-
trol) to 344 75 pg/mI in response to calcitriol, it decreased to
only 632 46 pg/ml in response to OCT, P < 0.01. The
magnitude of suppression achieved by OCT group was thus less
marked than that obtained with calcitriol. On the other hand,
both calcitriol and OCT increased blood Ca2 However, as
shown in Table 1, OCT had a less marked calcemic activity than
calcitriol after the injection during two subsequent days: 1.10
0.02 versus 1.23 0.04 m, compared with 1.02 0.03 m in
control rats (P < 0.01, control vs. OCT and calcitriol).
Duodenal calcium transport, duodenal calbindin-D9k protein
and mRNA. Twenty-four hours after the second OCT dose,
duodenal Ca transport remained unchanged compared with
control. In contrast, it was stimulated by exogenous calcitriol:
the ratio S/M was 7.0 0.6 for calcitriol, 3.7 0.3 for OCT, and
2.8 0.4 for control, P < 0.01 (Fig. 2). Duodenal calbindin-D9k
protein content and calbindin-D9k mRNA increased in re-
sponse to both OCT and calcitriol: calbindin-D9k, 8.5 1.2
(OCT) and 8.9 1.3 (calcitriol) jxg/mg protein, compared with
2.4 0.7 pg/mg for control, P < 0.01 (Fig. 2); calbindin-D9k
mRNA, 1.0 (OCT), and 1.1 (calcitriol) arbitrary units compared
with 0.5 arbitrary units for control (Fig. 3).
Five-day administration (series 2)
Plasma biochemistry. Plasma levels of phosphate, creatinine,
urea, alkaline phosphatases and total protein were not different
between the three groups (Table 1).
Plasma iPTHJ34 and blood Ca2t As shown in Figure 4, OCT
had less capacity than calcitriol to decrease plasma iPTH134:
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Control Calcitriol OCT
Fig. 2. Effect on duodenal Ca transport (; SIM) and calbindin-D9K()after two days of i.p. administration of either vehicle, calcitriol, 0.3
pg/rat (250 pmol/100 g body wt) or OCT. 0.3 pg/rat (250 pmol/100 g
body wt) 48 and 24 hours prior to sacrifice. Duodenal Ca transport was
significantly stimulated by calcitriol but not by OCT. In contrast,
duodenal calbindin-D9K content significantly increased to a similar
extent with OCT and calcitriol. * P < 0.01, calcitriol vs. control and
OCT; ** P < 0.01, calcitriol and OCT vs. control.
281 64 pg/mI (OCT) and 110 26 pg/mi (calcitriol) versus 624
135 pg/mi (control), P < 0.01 versus control. This decrease
was observed concomitantly with an increase in blood Ca24
compared with control (Table 1). The increase in blood Ca24
was comparable for OCT (0.3 sg/rat) and calcitriol (0.05 jsg/rat),
even though the dose of OCT injected was six times greater
than that of calcitriol.
Duodenal calcium transport and calbindin-D9k protein. Un-
like calcitriol, OCT treatment during five days did not increase
the duodenal Ca transport (S/M) which was measured 24 hours
after the last dose: 3.0 0.09 (OCT) versus 4.0 0.3 (calcitriol)
versus 2.6 0.3 (control); P < 0.05, control and OCT versus
calcitriol. In contrast, duodenal protein content increased in
response to both OCT and caicitriol: 11.5 1.6 pg/mg (OCT)
and 13.8 2.7 pg/mg protein (calcitriol) compared with 3.4
0.8 p.g/mg for control, P < 0.01 (Fig. 5).
Discussion
The main findings of the present study in uremic rats with
severe secondary hyperparathyroidism were: (1) that OCT
exerted less marked suppressive effects on plasma PTH levels
than calcitriol; (2) that OCT was not devoid of a calcemic
action; and (3) that OCT, in contrast to calcitriol, did not
stimulate active intestinal Ca transport under the conditions of
the present experiments, even though intestinal calbindin-D9k
protein content and calbindin-D9k mRNA expression were
comparably increased by OCT and caicitriol.
When analyzing the results of our study in more detail, the
short-term administration of a high dose of OCT. namely 0.3
jsg/rat per day during two subsequent days, led to an interme-
diate effect on plasma PTH level (decrease) and on blood Ca2
(increase), compared with the effects of calcitriol. Therefore,
we reasoned that if OCT had a more marked direct effect on
PTH synthesis than calcitriol with a similar or less pronounced
action on blood Ca24, one should be able to demonstrate such
a difference by the administration of relatively lower doses of
caicitriol than of OCT. Therefore, we elected to proceed to a
more prolonged treatment (5 days) of uremic rats by with the
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Fig. 4. Plasma iPTH,.34 after five days of i.p. administration of either
vehicle, calcitriol, 0.05 pg/rat (40 pmol/100 g body wt) or OCT, 0.3
rsg/rat (250 pmol/I00 g body WI). Mean SEM values are also indicated.
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Fig. 5. Effect of five days of i.p. administration of either vehicle,
calcitriol, 0.05 /.Lg/rat (40 pmol/100 g body WI) or OCT, 0.3 pg/rat (250
pmol/100 g bd WI) Ofl duodenal Ca transport (•; SIM) and duodenal
calbindin-D9K (0). Ca transport was measured 24 hours after the last
dose. * P < 0.05, ** P < 0.01.
Control Calcitriol OCT
Fig. 3. Calbindin-D9K mRNA expression after two days of i.p. admin-
istration of either vehicle, calcitriol, 0.3 jsg/rat (250 pmol/100 g body wt)
or OCT. 0.3 pg/rat (250 pmol/100 g body WI).
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same daily OCT dose as above, compared with a sixfold lower
calcitriol dose (0.05 pg/rat). Under these conditions, both
compounds increased blood Ca2. However, OCT was only as
effective as, but clearly not more active than, calcitriol in
reducing circulating PTH. Fukagawa et al [9] had also to use a
fivefold greater dose of OCT than of calcitriol to reach similar
effects in terms of inhibition of PTH secretion and PTH mRNA
expression. It was not possible to determine on the basis of
these results which percentage of plasma PTH reduction was
accounted for by the increase in blood Ca2 caused by vitamin
D derivatives. A direct inhibitory effect of OCT on PTH
synthesis has previously been demonstrated by other workers
[10, 11], but further studies are needed to determine whether
OCT is able to inhibit PTH secretion as efficiently as calcitriol
without elevating plasma calcium, in the setting of severe
secondary hyperparathyroidism.
Our findings differ from the observations reported by Fuka-
gawa et al [9]. These authors showed that similarly high doses
of OCT (200 pmolIlOO g body wt) given to mildly uremic rats
during two subsequent days inhibited PTH mRNA and de-
creased serum PTH levels towards normal values in the ab-
sence of hypercalcemia. The difference between their results
and ours could be explained by the fact that these rats had a
more moderate degree of chronic renal failure and a only mild
hyperparathyroidism, being fed with a normal calcium and
phosphate diet (0.6% Ca; 0.6% P). In contrast, our animals had
a more severe secondary hyperparathyroidism induced by a
higher phosphorus diet (1.2%) [22] and probably by a more
severe degree of chronic renal failure.
Another factor which could explain the relatively less marked
inhibition of serum PTH secretion by OCT in our model of
chronic renal failure in comparison to calcitriol is the pharma-
cokinetic differences between the two compounds [23, 24]. It
has been shown that OCT has a shorter plasma half-life than
calcitriol [25]. It is therefore possible that in the presence of
severe secondary hyperparathyroidism a longer exposure time
of the parathyroid glands to this vitamin D analog is necessary
to reach maximal capacity of inhibition.
In contrast to the initial report by Brown et al [10], another
more recent study of the same group [7, 26], as well as our
present findings, indicate that OCT rises plasma calcium levels.
Finch et al [26] showed that in normal rats OCT was able to
inhibit PTH mRNA and to increase urinary calcium excretion
without inducing hypercalcemia. However, when parathyroid-
ectomized rats were infused with PTH via osmotic minipumps
to achieve normal serum Ca, OCT significantly increased cir-
culating calcium levels. They concluded that OCT possessed a
calcemic activity which was probably masked by both its
suppressive action on PTH and the loss of Ca into the urine. On
the basis of these observations, we think that one of the reasons
for the rise of blood Ca2 induced by OCT in our uremic model
is the incapacity of OCT to return extremely high plasma PTH
levels towards the range of normal. Another reason could be
that OCT has the same properties as calcitriol in improving the
calcemic response to parathyroid hormone in uremic rats [27],
although it was not possible to prove this hypothesis in our
study.
In addition, in chronic renal failure, the calcemic action of
OCT, like that of calcitriol, is theoretically due mainly to an
increase in intestinal Ca absorption andlor in bone resorption.
In our study, active duodenal Ca transport was significantly
increased in the calcitriol treated rat group, but not in the group
receiving OCT. However, it has been recently shown that OCT
exerted a direct, but only transient stimulatory effect on intes-
tinal Ca absorption in vitamin D deficient rats. The same group
[28] showed that a seven-day OCT treatment (i.p.) in normal
rats, at the dose of 480 pmollrat, significantly increased the
percent of intestinal calcium absorption compared with the
control group. We have performed additional experiments in
normal and acutely uremic rats where we also found that OCT
had a potency similar to that of calcitriol in increasing duodenal
Ca absorption by four hours after its administration (data not
shown). Duodenal Ca absorption at 24 hours in response to
OCT was not different from that of control rats, in contrast to
the stimulation of Ca transport induced by calcitriol at 24 hours.
Thus, we confirm that OCT has a direct, but only transient,
effect on intestinal Ca absorption. These observations strongly
suggest that in the severely uremic rats of our present study,
there was an early increase of duodenal Ca absorption in
response to OCT which went undetected due to the experimen-
tal conditions.
The participation of bone resorption in the calcemic action of
OCT is probably less important than that of the intestinal route.
OCT mimics the genomic actions of calcitriol in bone cells, as
has been shown by the induction of osteocalcin synthesis and
alkaline phosphatase activity in MG-63 cells [29] and ROS
17/2.8 cells [30] in vitro. However, the bone mobilizing activity
of OCT in vivo is probably low [26, 31].
Interestingly, OCT treatment caused an increase in duodenal
caibindin-D9k protein content and calbindin-D9k mRNA ex-
pression which was similar to that induced by calcitriol. Since
OCT did not stimulate intestinal Ca transport, in contrast to
calcitriol, this finding indicates a dissociation between the two
vitamin D dependent events, or at least a different association
from that induced by calcitriol. OCT probably reacted with the
intestinal vitamin D receptor since it appeared capable to
increase the expression of calbindin-D9k mRNA and induce
calbindin-D9k synthesis. It is possible that a more rapid disso-
ciation of OCT from its receptor, its short half-life, or a less
potent induction of postreceptor events prevent a sustained
increase in intestinal Ca transport up to 24 hours after its
administration.
Although calbindin-D9k induction by calcitriol is well estab-
lished [21, 32], the precise role of this Ca binding protein in
intestinal Ca transport remains unclear. A detailed analysis of
the time course of duodenal Ca transport and calbindin in
response to calcitriol administration failed to support the con-
tention that calbindin played a major role in the stimulation of
transintestinal Ca movement [33—36]. In accord with this find-
ing, other authors [37] demonstrated that 16 hours after OCT
administration to vitamin D-deficient rats the intestinal trans-
port of Ca returned to the basal level, whereas duodenal
calbindin-D9k mRNA remained elevated up to 24 hours. Addi-
tional work is clearly required to better understand the role of
this protein.
In conclusion, in this model of secondary hyperparathyroid-
ism, OCT given at a high dose possesses a calcemic activity.
When injected over a five-day period in higher dose than
calcitriol to obtain a comparable degree of mild hypercalcemia,
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OCT has no greater capacity than calcitriol to decrease circu-
lating PTH in uremic rats. Both vitamin D analogs were
equivalent in increasing duodenal calbindin-D9k mRNA and
protein synthesis, but only calcitriol stimulated intestinal cal-
cium transport. Further studies are necessary to discover
whether OCT has a clear cut advantage over calcitriol in the
management of secondary hyperparathyroidism.
Reprint requests to Ti!man B. Drüeke, M.D., 1NSERM Unite 90,
Hópita! Necker, 161 rue de Sèvres, 75743 Paris Cedex 15, France.
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